KRAS and neoplasm: Using a medicinal chemistry approach, other compounds were discovered: TH-Z827 and TH-Z835 are two inhibitors that bind with Asp12 inside the switch-II pocket, specifically inhibiting KRAS signaling, and not KRASG12C or WT, in G12D mutant PDAC in vitro and in vivo; in vitro, KD-8 is another inhibitor of KRASG12D PDAC tumor growth [33].